Independent biopharmaceutical company Specialised Therapeutics Asia (ST) announced that a new therapy to treat rare gastrointestinal stromal tumours (GIST) shown to improve survival has been approved for use in Singapore.
The therapy, Qinlock (ripretinib) is now approved by the Health Sciences Authority (HSA)
